Market Overview

Vetr Top Raters Upgrade Juno Therapeutics To 4.5-Star Stock


Shares of Juno Therapeutics Inc (NASDAQ: JUNO) have lost nearly 25 percent of its value since the start of 2016 which likely prompted Vetr top raters to recognize value in its stock at a deflated price.

Vetr top raters upgraded Juno Therapeutics' stock rating to 4.5-stars out of a possible 5-stars. In fact, shares of Juno Therapeutics have risen to $33.71 since the prior rating of 3.5-stars was issued just 6 days ago.

Related link: Here's how crowdsourced ratings can beat the market.

In addition to being upgraded to bull territory, 100 percent of the crowd's ratings are bullish and the crowd sourced price target of $37.81 implies a potential upside of more than 12 percent.


Related Articles (JUNO)

View Comments and Join the Discussion!

Posted-In: undefinedAnalyst Color Crowdsourcing General

Latest Ratings

WWEEvercore ISI GroupUpgrades
INTB of A SecuritiesUpgrades40.0
BLDPBMO CapitalInitiates Coverage On39.0
SSYSStifelInitiates Coverage On40.0
CMGGoldman SachsInitiates Coverage On1,650.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at